Risk of Acute Ischemic Stroke in Patients 65 and Older Is Early After COVID-19 Diagnosis

Alexis N. Simpkins, MD, PhD, MSCR, and Alain Lekoubou, MD, MS

Neurology® 2022;98:301-302. doi:10.1212/WNL.0000000000013182

Associated acute and long-term medical complications of COVID-19 beyond respiratory illness include acute ischemic stroke (AIS).1-3 Hypercoagulability, inflammation, cardiac dysfunction, and endothelial inflammation that occur during the infectious phase can lead to thrombotic events and thus cerebral ischemia.4-5 Reported risks of stroke in COVID-19 have varied substantially across studies.6 Most studies have focused on AIS incidence in patients diagnosed during or upon hospitalization. Unlike any other infectious disease in modern times and as a result of the need to trace and monitor for outbreaks to prevent the spread of COVID-19, a very large number of patients have been screened for COVID-19 at the time of hospital admission. This screening has identified both asymptomatic and symptomatic individuals with COVID-19, thus making it more difficult to determine whether and in whom COVID-19 may increase the risk of AIS and whether the association is true or incidental. In this issue of Neurology®, Yang et al.8 evaluated the estimated incidence rate ratio of AIS after COVID-19 infection in a known high-risk group—patients older than 65—and determined the time frame of highest risk of AIS associated with COVID-19 within this population.8

The authors used inpatient and outpatient fee-for-service Medicare claims to identify 37,379 patients with COVID-19 and AIS between January 2019 and February 2021.7 A pre-COVID diagnosis phase was used to account for unknown possible inoculation times and the time frame from COVID-19 billing diagnosis to stroke billing diagnosis code of up to 28 days was evaluated.8 Applying the self-controlled case series method, the authors found that the incidence rate ratios (IRRs) were highest within 3 days of diagnosis of COVID-19, with an odds ratio of 10.3 (95% confidence interval 9.86–10.8), and that the estimated IRR was higher in those between ages 65 and 74 without a prior history of stroke.8 By contrast, the association between stroke and COVID-19 was weaker 15–28 days after the initial diagnosis, suggesting that AIS rarely manifests as a long-term COVID-19 sequela in elderly patients.8 Major strengths of the study are the inclusion of COVID-19 cases diagnosed both in outpatient and inpatient settings, the inclusion of a large number of patients from minority groups, and the use of robust statistical methods, such as the self-case-controlled case study, which has the advantage of implicit control for all fixed confounding effects. The authors made a great effort to verify that all assumptions were not violated, albeit with some modifications. They solidified the findings of their study by performing a number of sensitivity analyses.

Interpretation of the study results should consider potential limitations, which were described by Yang et al.8 These limitations stem primarily from the retrospective nature of the analysis and the use of administrative claims to identify cases of COVID-19 and AIS. As the Medicare data are updated monthly, cases of COVID-19 and deaths could have been missed. Also, rapid changes in the entire health care system during the COVID-19 pandemic, including access to preventative care, patient presentation to health care facilities for evaluation of stroke-like symptoms, availability of testing and procedures, and acute stroke care, could have affected the results and the applicability of the self-controlled case study.8
The study has important clinical implications. The authors identified both a group of patients (65–74 years without a prior history of stroke) and a critical period (first 3 days) for which the risk of AIS after COVID-19 diagnosis is highest. These raise important questions: Should patients aged 65–74 years be treated more preemptively and aggressively to prevent ischemic stroke? What would be the ideal duration of such specific interventions? Well-designed clinical trials are needed to answer these questions.

**Study Funding**
The authors report no targeted funding.

**Disclosure**
The authors report no disclosures. Go to Neurology.org/N for full disclosures.

**References**

Risk of Acute Ischemic Stroke in Patients 65 and Older Is Early After COVID-19 Diagnosis
Alexis N. Simpkins and Alain Lekoubou
Neurology 2022;98;301-302 Published Online before print February 3, 2022
DOI 10.1212/WNL.0000000000013182

This information is current as of February 3, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/98/8/301.full

References
This article cites 9 articles, 2 of which you can access for free at:
http://n.neurology.org/content/98/8/301.full#ref-list-1

Citations
This article has been cited by 1 HighWire-hosted articles:
http://n.neurology.org/content/98/8/301.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cerebrovascular disease/Stroke
http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke
All epidemiology
http://n.neurology.org/cgi/collection/all_epidemiology
All Health Services Research
http://n.neurology.org/cgi/collection/all_health_services_research
COVID-19
http://n.neurology.org/cgi/collection/covid_19
Stroke prevention
http://n.neurology.org/cgi/collection/stroke_prevention

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise